Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Intra-Nasale Mechanische Stimulatie (INMEST) als een Potentieel Preventieve Behandeling voor Migraine (A-MI-01)

2 november 2026 bijgewerkt door: Abilion Medical Systems AB

Intra-Nasale Mechanische Stimulatie (INMEST) als Mogelijke Preventieve Behandeling voor Migraine - Een Prospectieve, Gerandomiseerde, Open Label, Uitgestelde-Start Studie om de Veiligheid en Prestaties van het Walther Systeem te Evalueren

This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical stimulation (INMEST), as a preventative treatment for migraine. A total of 110 adults (18-65 years) with a history of migraine will be randomized 1:1 into two groups: Group A (early treatment) and Group B (delayed treatment). The study includes baseline assessments, in-clinic device training, and home-based self-administered treatments every second day for six weeks. The primary outcome is the change in monthly migraine days during the primary treatment comparison period. Secondary outcomes include headache days, migraine intensity, duration, rescue medication use, patient-reported outcomes, device compliance, and safety. The study will be conducted at one site in Sweden.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

110

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Stockholm, Zweden, 11327
        • INMEST-mottagningen Odenplan

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Age 18-65 years at the time of screening.

  2. The study subject must have a clinical diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-3), indicated by medical record shown by the subject.

  3. Onset of migraine headache occurred before age 50.

  4. History of migraines for at least 1 year before screening.

  5. The study subject reports at least 8 monthly migraine days during the screening period.

  6. If subject is on a prophylactic migraine medication regimen:

    1. Reports stable medication regimen during the three months prior to screening.
    2. Able and willing to maintain medication regimen (no change in type, frequency or dose) from screening to end of follow-up.
  7. The study subject reports having understood and have signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.

  8. Women of childbearing potential must agree to use a reliable, medically approved form of contraception during the study participation until end of study.

  9. Anticipated compliance with prescribed treatment and follow-up.

Exclusion Criteria:

  1. Subject unable to distinguish between migraine headaches and other headache types.
  2. Recently (12 months prior screening) undergone nasal or sinus surgery.
  3. Any severe diseases for which, in the opinion of the Investigator, participation would not be in the best interest of the subject or that can interfere with the performance, evaluation, and outcome of the clinical evaluation.
  4. Previous (within 30 days prior to screening) and concurrent treatment with another investigational drug/s or device/s.
  5. Subject is pregnant or lactating or planning to get pregnant during the duration of the study.
  6. The study subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation.
  7. The study subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Group A - Early Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), then receive active treatment with the Walther System every second day for 6 weeks (weeks 5-10). The first treatment is performed under supervision at the clinic, and subsequent treatments are self-administered at home. Post-treatment assessments occur during weeks 11-14.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Andere namen:
  • Walther System
Actieve vergelijker: Group B - Delayed Start

Subjects undergo a 4-week baseline assessment (weeks 1-4), followed by a 6-week no-treatment reference period (weeks 5-10). Active treatment with the Walther System is then administered every second day for 6 weeks (weeks 11-16), starting with an initial supervised treatment at the clinic. Post-treatment assessments occur during weeks 17-20.

Hand-held controller and catheter assembly for intra-nasal mechanical stimulation (INMEST), self-administered at home every second day for 6 weeks, first treatment under supervision.

Andere namen:
  • Walther System

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Monthly Migraine Days
Tijdsspanne: Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Between-group comparison of the difference in mean change in monthly migraine days from the baseline assessment period (weeks 1-4) to Group A) Treatment performance period (weeks 7-10) and Group B) No treatment reference period (weeks 7-10).

Weeks 7-10 (Group A: Treatment performance period; Group B: No treatment reference period)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Mean change in monthly headache days
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change in monthly headache days from baseline.

Weeks 7-10
Mean change in migraine intensity
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change in migraine intensity from baseline.

Weeks 7-10
Mean change in duration of migraine attacks
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change in migraine attack duration (hours) from baseline.

Weeks 7-10
Proportion of attacks requiring rescue medication
Tijdsspanne: Weeks 7-10

Between-group comparison of the proportion of migraine attacks requiring rescue medication.

Weeks 7-10
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Tijdsspanne: Weeks 7-10

Between-group comparison of the proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days.

Weeks 7-10
Mean change in PROMIS-PI SF-6b
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PROMIS-PI SF-6b scores. The raw scores are converted to standardized T-scores (range 0-100; mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Weeks 7-10
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in MSQ scores. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Weeks 7-10
Mean change in Patient Global Impression of Severity (PGI-S)
Tijdsspanne: Weeks 7-10

Between-group comparison of the difference in mean change from baseline in PGI-S scores. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Weeks 7-10
Mean change in monthly migraine days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity within each group. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours) within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days within each group.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores within each group. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores within each group. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores within each group. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly migraine days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in monthly headache days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in monthly headache days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in migraine intensity (6-point severity scale)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in migraine intensity, pooled across both groups. Migraine intensity is assessed using a 6-point severity scale (1 = Very mild, 6 = Very severe), where higher scores indicate greater pain severity."

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in duration of migraine attacks
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in duration of migraine attacks (hours), pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of migraine attacks requiring rescue medication
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of migraine attacks requiring rescue medication, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Number of participants with ≥30% and ≥50% reduction in monthly migraine days
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Proportion of subjects achieving ≥30% and ≥50% reduction in monthly migraine days, pooled across both groups.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in PROMIS-PI SF-6b
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b scores, pooled across both groups. The raw scores are converted to standardized T-scores (mean = 50, SD = 10) based on the PROMIS calibration sample. Higher scores indicate greater pain-related interference.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Migraine-Specific Quality of Life Questionnaire (MSQ)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PROMIS-PI SF-6b, MSQ, and PGI-S scores, pooled across both groups. Scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Mean change in Patient Global Impression of Severity (PGI-S)
Tijdsspanne: Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20

Change from baseline in PGI-S scores, pooled across both groups. Measured on a 7-point scale (1 = least severe, 7 = most severe), where higher values indicate greater severity.

Group A: Weeks 1-4 → 11-14; Group B: Weeks 7-10 → 17-20
Proportion of prescribed treatments completed
Tijdsspanne: Throughout the 6-week treatment period

Compliance based on device usage logs or participant-reported treatment diaries.

Throughout the 6-week treatment period
Adverse Events / Serious Adverse Events / Device Effects
Tijdsspanne: Through study completion (14 or 20 weeks, depending on treatment group)

Number of treatment-related AEs, SAEs, ADEs, SADEs, and Unanticipated SADEs for the Walther System.

Through study completion (14 or 20 weeks, depending on treatment group)
Device Deficiencies
Tijdsspanne: Throughout the 6-week treatment period

Number of device deficiencies for the Walther System.

Throughout the 6-week treatment period

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Device usability and user experience (combined questionnaires)
Tijdsspanne: Throughout the 6-week treatment period

User-reported usability, ease of use, handling, and overall experience of the device during home use, assessed using two Device Usability Questionnaires. Questions include multiple 3- or 5-point scales, 0-10 scales, and yes/no responses. Higher scores indicate better usability or greater interest where applicable.

Throughout the 6-week treatment period
Symptom trends (Symptom Questionnaire)
Tijdsspanne: Throughout the 6-week treatment period

Changes in symptoms potentially related to autonomic nervous system function, assessed using the Symptom Questionnaire at Visits 1-5. The questionnaire includes multiple items with 0-6 and 0-3 ordinal scales, yes/no responses, and other response formats. Higher scores indicate more severe symptoms."

Throughout the 6-week treatment period

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Jan-Erik Juto, PhD, MD

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

21 oktober 2025

Primaire voltooiing (Geschat)

1 november 2026

Studie voltooiing (Geschat)

1 november 2026

Studieregistratiedata

Eerst ingediend

18 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

10 december 2025

Eerst geplaatst (Werkelijk)

12 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren